Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer

NCT00055432 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00055432
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00055432 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Terminated
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer, peritoneal cancer